Can Intestinal Phosphate Binding or Inhibition of Hydroxyapatite Growth in the Vascular Wall Halt the Progression of Established Aortic Calcification in Chronic Kidney Disease?
Authors:
- 26 July 2016
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 99 (5) , 525-534
Abstract
Vascular calcification significantly contributes to mortality in chronic kidney disease (CKD) patients. Sevelamer and pyrophosphate (PPi) have proven to be effective in preventing vascular calcification, the former by controlling intestinal phosphate absorption, the latter by directly interfering with the hydroxyapatite crystal formation. Since most patients present with established vascular calcification, it is important to evaluate whether these compounds may also halt or reverse the progression of preexisting vascular calcification. CKD and vascular calcification were induced in male Wistar rats by a 0.75 % adenine low protein diet for 4 weeks. Treatment with PPi (30 or 120 µmol/kg/day), sevelamer carbonate (1500 mg/kg/day) or vehicle was started at the time point at which vascular calcification was present and continued for 3 weeks. Hyperphosphatemia and vascular calcification developed prior to treatment. A significant progression of aortic calcification in vehicle-treated rats with CKD was observed over the final 3-week period. Sevelamer treatment significantly reduced further progression of aortic calcification as compared to the vehicle control. No such an effect was seen for either PPi dose. Sevelamer but not PPi treatment resulted in an increase in both osteoblast and osteoid perimeter. Our study shows that sevelamer was able to reduce the progression of moderate to severe preexisting aortic calcification in a CKD rat model. Higher doses of PPi may be required to induce a similar reduction of severe established arterial calcification in this CKD model.Keywords
Funding Information
- Baxter Healthcare Corporation (A10/0650)
This publication has 38 references indexed in Scilit:
- Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremiaKidney International, 2013
- Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature CommitteeJournal of Bone and Mineral Research, 2012
- Treatment with pyrophosphate inhibits uremic vascular calcificationKidney International, 2011
- Role of calcium-phosphate deposition in vascular smooth muscle cell calcificationAmerican Journal of Physiology-Cell Physiology, 2011
- Chondrocyte Rather Than Osteoblast Conversion of Vascular Cells Underlies Medial Calcification in Uremic RatsArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failureKidney International, 2009
- Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular calcificationKidney International, 2008
- Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysisKidney International, 2005
- Reduced Plasma Pyrophosphate Levels in Hemodialysis PatientsJournal of the American Society of Nephrology, 2005
- Does the Phosphate Binder Lanthanum Carbonate Affect Bone in Rats with Chronic Renal Failure?Journal of the American Society of Nephrology, 2004